Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176791
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBruni, Laia-
dc.contributor.authorSaura Lázaro, Anna-
dc.contributor.authorMontoliu, Alexandra-
dc.contributor.authorBrotons, Maria-
dc.contributor.authorAlemany i Vilches, Laia-
dc.contributor.authorDiallo, Mamadou Saliou-
dc.contributor.authorAfsar, Oya Zeren-
dc.contributor.authorLamontagne, D. Scott-
dc.contributor.authorMosina, Liudmila-
dc.contributor.authorContreras, Marcela-
dc.contributor.authorVelandia González, Martha-
dc.contributor.authorPastore, Roberta-
dc.contributor.authorGacic Dobo, Marta-
dc.contributor.authorBloem, Paul-
dc.date.accessioned2021-04-29T13:38:46Z-
dc.date.available2021-04-29T13:38:46Z-
dc.date.issued2021-03-01-
dc.identifier.urihttp://hdl.handle.net/2445/176791-
dc.description.abstractWHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B. V.-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ypmed.2020.106399-
dc.relation.ispartofPreventive Medicine, 2021, vol. 144-
dc.relation.urihttps://doi.org/10.1016/j.ypmed.2020.106399-
dc.rightscc by-nc-nd (c) Bruni et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCàncer de coll uterí-
dc.subject.classificationVacuna del papil·lomavirus-
dc.subject.otherCervix cancer-
dc.subject.otherPapillomavirus vaccines-
dc.titleHPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-04-29T09:45:41Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33388322-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S0091743520304308-main.pdf8.26 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons